Philips makes another digital buy, as Thermo adds COVID-19 test makerBetween them, Royal Philips and Thermo Fisher have been driving a mini M&A spree in the medical technology Share XPhilips makes another digital buy, as Thermo adds COVID-19 test makerhttps://pharmaphorum.com/news/philips-makes-another-digital-buy-as-thermo-adds-covid-19-test-device/
Biden appoints veteran Woodcock as interim FDA commissionerAgency veteran Dr Janet Woodcock is the new interim FDA commissioner appointed by president Joe Biden to replace Share XBiden appoints veteran Woodcock as interim FDA commissionerhttps://pharmaphorum.com/news/biden-appoints-veteran-woodcock-as-interim-fda-commissioner/
GSK/Merck & Co’s hopeful bintrafusp alfa fails in key lung cancer trialGlaxoSmithKline’s big gamble on a cancer drug developed by Germany’s Merck KGaA looks unlikely to pay out, after Share XGSK/Merck & Co’s hopeful bintrafusp alfa fails in key lung cancer trialhttps://pharmaphorum.com/news/gsk-merck-cos-hopeful-bintrafusp-alfa-fails-in-key-lung-cancer-trial/
Pfizer/BioNTech say COVID-19 vaccine works against UK variantLaboratory studies have confirmed that antibodies stimulated by Pfizer and BioNTech’s COVID-19 vaccine can neutralise the new, more Share XPfizer/BioNTech say COVID-19 vaccine works against UK varianthttps://pharmaphorum.com/news/pfizer-biontech-say-covid-19-vaccine-works-against-uk-variant/
ARK promotes King to client services director, hires Rodriguez as art directorLondon-based comms agency ARK has promoted Nicky King to client services director, with Martina Germinario Rodriguez joining as Share XARK promotes King to client services director, hires Rodriguez as art directorhttps://pharmaphorum.com/news/ark-promotes-king-to-client-services-director-hires-rodriguez-as-art-director/
Lilly bolts on cancer bispecifics with $1.6bn Merus allianceAlways a big player in oncology, Eli Lilly has fallen behind some of its rivals when it comes Share XLilly bolts on cancer bispecifics with $1.6bn Merus alliancehttps://pharmaphorum.com/news/lilly-bolts-on-cancer-bispecifics-with-1-6bn-merus-alliance/
Sobi gets EU nod for Doptelet in rare blood disorder ITPSweden’s Sobi has secured EU approval for Doptelet in primary chronic immune thrombocytopenia (ITP), an indication that the Share XSobi gets EU nod for Doptelet in rare blood disorder ITPhttps://pharmaphorum.com/news/sobi-gets-eu-nod-for-doptelet-in-rare-blood-disorder-itp/
ConserV Bioscience works on mutation-proof coronavirus shots with US labUK biotech ConserV Bioscience has joined with California’s Lawrence Livermore National Laboratory to develop broad-spectrum coronavirus vaccines as Share XConserV Bioscience works on mutation-proof coronavirus shots with US labhttps://pharmaphorum.com/news/conserv-bioscience-working-on-mutation-proof-coronavirus-shot-with-us-lab/
One in 11 over-65s unwilling to take COVID-19 shotOne in 11 adults aged over 65 have reported a lack of willingness to receive a COVID-19 vaccine, Share XOne in 11 over-65s unwilling to take COVID-19 shothttps://pharmaphorum.com/news/one-in-11-older-patients-unwilling-to-take-covid-19-shot/
Careology joins forces with remote care support firm RedArcDigital cancer care platform Careology has joined forces with RedArc, which provides long-term support for people with serious Share XCareology joins forces with remote care support firm RedArchttps://pharmaphorum.com/news/careology-joins-forces-with-care-support-firm-redarc/
COVID-19 vaccine supplies in spotlight as immunisation campaigns kick inSupplies of COVID-19 vaccines are in the spotlight as countries across the world step up their immunisation campaigns Share XCOVID-19 vaccine supplies in spotlight as immunisation campaigns kick inhttps://pharmaphorum.com/news/covid-19-vaccine-supplies-in-spotlight-as-immunisation-campaigns-kick-in/
Scotland backs Roche’s Rozlytrek for ROS1 lung cancerThe Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of Share XScotland backs Roche’s Rozlytrek for ROS1 lung cancerhttps://pharmaphorum.com/news/scotland-backs-roches-rozlytrek-for-ntrk-tumours/
ViiV launches digital triage service for HIV patients with London hospitalViiV Healthcare and London’s Westminster Hospital NHS Foundation Trust have launched a digital triage service for HIV patients Share XViiV launches digital triage service for HIV patients with London hospitalhttps://pharmaphorum.com/news/viiv-launches-digital-triage-service-for-hiv-patients-with-london-hospital/
NHS and Kite sign access deal for Kite’s cancer cell therapy TecartusNHS patients in England will be among the first in the world to receive Gilead’s Tecartus cancer cell Share XNHS and Kite sign access deal for Kite’s cancer cell therapy Tecartushttps://pharmaphorum.com/news/nhs-kite-cancer-therapy/
Allergic reactions prompt Moderna COVID vaccine pause in CaliforniaPublic health authorities in California are seeking a halt on dosing of one lot of Moderna’s COVID-19 vaccine Share XAllergic reactions prompt Moderna COVID vaccine pause in Californiahttps://pharmaphorum.com/news/allergic-reactions-prompt-california-to-seek-moderna-covid-vaccine-pause/
Fauci backs Biden’s plan for 100 million COVID-19 shotsA promise by president-elect Joe Biden to carry out 100 million coronavirus vaccinations in his first 100 days Share XFauci backs Biden’s plan for 100 million COVID-19 shotshttps://pharmaphorum.com/news/fauci-backs-bidens-plan-for-100-million-covid-19-shots/
AZ/Daiichi Sankyo’s Enhertu gets second US cancer indicationAstraZeneca and Daiichi Sankyo’s Enhertu cancer drug has picked up a second indication, in patients who have stomach Share XAZ/Daiichi Sankyo’s Enhertu gets second US cancer indicationhttps://pharmaphorum.com/news/az-daiichi-sankyos-enhertu-gets-second-us-cancer-indication/
J&J’s Darzalex Faspro is first US therapy for rare blood disorderJohnson & Johnson’s Darzalex Faspro has become the first product approved by the FDA to treat light chain Share XJ&J’s Darzalex Faspro is first US therapy for rare blood disorderhttps://pharmaphorum.com/news/jjs-darzalex-faspro-is-first-us-therapy-for-rare-blood-disorder/
Using Define-XML for Dataset Design Share XUsing Define-XML for Dataset Designhttps://pharmaphorum.com/partner-content/using-define-xml-for-dataset-design/
UK Innovators Target Nanoparticles at Inoperable Cancers Share XUK Innovators Target Nanoparticles at Inoperable Cancershttps://pharmaphorum.com/partner-content/uk-innovators-target-nanoparticles-at-inoperable-cancers/
Patient experiences are evolving. How can pharma keep up? Share XPatient experiences are evolving. How can pharma keep up?https://pharmaphorum.com/partner-content/patient-experiences-are-evolving-how-can-pharma-keep-up/
Machine-learning, robotics and biology to deliver drug discovery of tomorrow Share XMachine-learning, robotics and biology to deliver drug discovery of tomorrowhttps://pharmaphorum.com/partner-content/machine-learning-robotics-and-biology-to-deliver-drug-discovery-of-tomorrow/
Prescient Healthcare Group to Partner with Bridgepoint Development Capital Share XPrescient Healthcare Group to Partner with Bridgepoint Development Capitalhttps://pharmaphorum.com/partner-content/prescient-healthcare-group-to-partner-with-bridgepoint-development-capital/
Prescient Announces Recent Appointments to its Senior Team Share XPrescient Announces Recent Appointments to its Senior Teamhttps://pharmaphorum.com/partner-content/prescient-announces-recent-appointments-to-its-senior-team/
